Innate Pharma S.A. (LON: 0EVI)
London
· Delayed Price · Currency is GBP · Price in EUR
1.775
+0.029 (1.66%)
At close: Jan 22, 2025
Innate Pharma Revenue
Innate Pharma had revenue of 12.35M EUR in the half year ending June 30, 2024, a decrease of -72.92%. This brings the company's revenue in the last twelve months to 33.79M, down -35.37% year-over-year. In the year 2023, Innate Pharma had annual revenue of 61.64M with 6.88% growth.
Revenue (ttm)
33.79M EUR
Revenue Growth
-35.37%
P/S Ratio
n/a
Revenue / Employee
188.76K EUR
Employees
179
Market Cap
123.61M GBP
Revenue Chart
* This company reports financials in EUR.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 61.64M | 3.97M | 6.88% |
Dec 31, 2022 | 57.67M | 32.97M | 133.47% |
Dec 31, 2021 | 24.70M | -45.07M | -64.60% |
Dec 31, 2020 | 69.77M | -15.68M | -18.35% |
Dec 31, 2019 | 85.45M | -8.50M | -9.05% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Shell | 221.41B |
AstraZeneca | 38.20B |
HSBC Holdings | 43.25B |
Unilever | 51.12B |
Rio Tinto Group | 42.87B |
RELX PLC | 9.30B |
BP p.l.c. | 144.69B |
British American Tobacco p.l.c. | 26.18B |